Get the latest Science News and Discoveries
Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen ... - EurekAlert
The follow-on analysis of results from the phase 3 PSMAfore study, along with the overall study results, support the consideration of <sup>177</sup>Lu-PSMA-617 as a new standard treatment approach for this prevalent population of patients with mCRPC. Research led by Dana-Farber Cancer Institute and elsewhere.
None
Or read this on Eureka Alert